A detailed history of Vanguard Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,539,590 shares of IBRX stock, worth $85.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,539,590
Previous 13,328,525 1.58%
Holding current value
$85.6 Million
Previous $66.9 Million 8.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$3.23 - $6.17 $681,739 - $1.3 Million
211,065 Added 1.58%
13,539,590 $72.7 Million
Q4 2023

Feb 14, 2024

SELL
$1.25 - $5.21 $1.68 Million - $7.02 Million
-1,347,162 Reduced 9.18%
13,328,525 $66.9 Million
Q3 2023

Nov 14, 2023

BUY
$1.29 - $3.1 $5.6 Million - $13.5 Million
4,342,386 Added 42.02%
14,675,687 $24.8 Million
Q2 2023

Aug 14, 2023

BUY
$1.53 - $6.41 $3.13 Million - $13.1 Million
2,047,343 Added 24.71%
10,333,301 $28.7 Million
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $41,461 - $146,803
30,712 Added 0.37%
8,285,958 $15.1 Million
Q4 2022

Feb 10, 2023

BUY
$4.35 - $6.77 $764,316 - $1.19 Million
175,705 Added 2.17%
8,255,246 $41.9 Million
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $2.03 Million - $3.58 Million
557,164 Added 7.41%
8,079,541 $40.2 Million
Q2 2022

Aug 12, 2022

BUY
$2.68 - $6.14 $981,499 - $2.25 Million
366,231 Added 5.12%
7,522,377 $28 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.53 $88,925 - $132,595
17,609 Added 0.25%
7,156,146 $40.1 Million
Q4 2021

Feb 14, 2022

BUY
$5.67 - $10.18 $608,271 - $1.09 Million
107,279 Added 1.53%
7,138,537 $43.4 Million
Q3 2021

Nov 12, 2021

BUY
$9.17 - $14.24 $13.5 Million - $21 Million
1,471,235 Added 26.46%
7,031,258 $68.5 Million
Q2 2021

Aug 13, 2021

BUY
$13.41 - $22.4 $74.6 Million - $125 Million
5,560,023 New
5,560,023 $79.4 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $2.53B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.